Elion Therapeutics key facts
as of Oct 2026- Provider of clinical research and development services intended to treat systemic and life-threatening fungal infections.
- Elion Therapeutics is valued at approximately $163.0M as of Oct 2026 (last reported valuation).
- It has raised $111.0M; the latest was Later Stage VC ($81.0M) in Aug 2025.
- Notable investors include Deerfield Management, Illinois Ventures, AMR Action Fund.
- Status: Privately Held (backing).
Elion Therapeutics's last reported valuation, Aug 2025. Nothing priced has surfaced since.
- ·Watch Elion Therapeutics: the Monday email on marks, rounds and moves
Elion Therapeutics funding rounds
No funding rounds for Elion Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Elion Therapeutics
3Elion Therapeutics valuation
Elion Therapeutics's last reported valuation was $163 million in Aug 2025. No priced round, secondary trade or fund mark has surfaced since.
Elion Therapeutics investors
3 investors are on record for Elion Therapeutics, including Deerfield Management, Illinois Ventures and AMR Action Fund.
About Elion Therapeutics
Provider of clinical research and development services intended to treat systemic and life-threatening fungal infections. The company's services focus on the improvement of the Amphotericin B drug, enabling patients to receive a broad spectrum of antifungal drugs that are completely non-toxic in mammalian cells.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2018
- Employees
- 13
- Website
- eliontx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.